Products for Research Use Only
RegisterLogin

JNJ-70218902

CAT: 0804-HY-P991172Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P991172Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JNJ-70218902 is a bispecific antibody that binds to human TMEFF2 on cancer cells and to human CD3 on T cells. JNJ-70218902 induces an exposure-dependent proinflammatory response and targeted tumor cell lysis, and promotes T cell-mediated tumor cell killing (EC50: 1.4 nM). JNJ-70218902 has a promising potential for prostate cancer research. The recommended isotype control is human IgG4 kappa, isotype control.
UNSPSC
12352203
Target
CD3; Transmembrane Glycoprotein
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
[JNJ-70218902]
References & Citations
[1]Basu S et al. Abstract LB087: Characterization of JNJ-70218902, a TMEFF2 x CD3 bispecific antibody, in prostate cancer models Cancer Research 82.12_Supplement (2022) : LB087-LB087. |[2]Lowenstein C, et al. 1360 Pharmacodynamics of JNJ-70218902, a TMEFF2x CD3 bispecific antibody, in cynomolgus monkey. (2022) .
Shipping Conditions
Room temperature
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 1

Related Products

CatalogName
HY-172194JNJ-3738
HY-113751-01JNJ-39393406
HY-132895JNJ-67569762
HY-118424-01JNJ-55511118
HY-110132-01JNJ-27141491
HY-19917-01JNJ-39220675
HY-123531JNJ 10329670
HY-148240-01JNJ-65355394
HY-111066-01JNJ-37822681
HY-120595-01JNJ-49095397

Alternative Products

CatalogName
T9901A-868-01JNJ-70218902
MBS131356JNJ-63533054 (JNJ63533054; JNJ 63533054)
BA6861-10JNJ-42253432
A4361-50JNJ-1661010
BA6753-5.1JNJ-61432059
BA6849-10JNJ-55308942
C4122-10JNJ-42165279
BA5559-5.1JNJ-40411813
B5553-5JNJ 10397049
B1574-10JNJ-7777120

Popular Products